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A b s t r a c t  
Idiopathic Pulmonary Fibrosis is a chronic lung disease characterized by lung inflammation and 
progression to fibrosis. Anti-fibrotic efficacy of lutein was studied in mouse model of bleomycin 
induced pulmonary fibrosis. The mice were orally administrated with 100 or 200 mg/kg of lutein three 
days prior to intra-tracheal instillation of bleomycin on day 0 and continued up to day 21. Total cell 
counts and protein levels in branchoalveolar lavage fluid and superoxide dismutase, and 
hydroxyproline levels were evaluated. Treatment with lutein at 100 and 200 mg/kg prevented 
bleomycin induced mortality and body weight loss. Lutein administration attenuated bleomycin 
induced increase of total and differential cell count and myeloperoxidase, inflammatory cell 
infiltration in lung tissue. Similarly lutein administration restored superoxide dismutase activity 
lowered by bleomycin instillation. The combined results revealed the protective effect of lutein by 
suppressing the inflammation, oxidative stress and enhancing the antioxidant potential which may 
helps in pulmonary fibrosis. 
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Introduction 
Idiopathic Pulmonary Fibrosis (IPF) is a chronic diffuse interstitial 
lung disease characterized by inflammation and fibrosis in lung 
parenchyma cells [1- 2]. The disease prevalence is estimated to be 
in the range of 3-5 per 100,000 people and the mean survival after 
diagnosis of the disease is 2.8-4.2 years [3]. Previous studies 
reported higher estimates of 20 per 100,000 males and 13 per 
100,000 females based on an Interstitial Lung Registry in Bernalillo 
County, New Mexico [4]. The process of fibrosis is dynamic, which 
involves infiltration of leukocytes, activation and proliferation of 
fibroblasts and accumulation of extracellular matrix proteins due to 
repeated and/or aberrant repair events leading to impaired gas 
exchange and respiratory failure [4-5]. Further, lung injury and 
inflammation is caused by the reactive oxygen species (ROS) 
which are released from activated leukocytes [6]. ROS and 
activated cytokines, especially transforming growth factor (TGF)-
β1, stimulate the abnormal wound repair and remodeling of lung by 
accumulation of collagen [7-8]. TGF-β1 stimulates the production 
of interstitial collagen through both activation of fibroblasts and 
transformation of fibroblasts to collagen producing myofibroblasts 
[9]. Although etiology of IPF is not known, cigarette smoking, 
environmental factors, infectious agents and exposure to certain 
chemotherapeutic drugs like bleomycin, etc. are some of the 
factors that cause IPF [10]. Since pulmonary fibrosis symptoms 
were observed in humans treated with bleomycin for various 
cancers, a number of studies have employed bleomycin-induced 
mice model for characterizing IPF [11]. Intra-tracheal administration 
of bleomycin in rodents has become the most widely used 
experimental model of lung fibrosis, which mimics the inflammatory 
and fibrotic events to human IPF [12]. The current treatment using 
corticosteroids and cytotoxic agents has not improved the 
prognosis of the disease [13]. Hence, an alternative strategy to 
develop safe, affordable, effective and economically feasible drugs 
such as natural products and/or dietary supplements is required for 
the treatment of IPF. It is well known that naturally available 
hydroxyl caroteniod, lutein, which is found in dark green leafy 
vegetables such as kale and spinach, has shown neuro-protective 
effect during retinal inflammation [14], atherosclerosis [15], 
endotoxin-induced uveitis [16] and cerebral ischemia/reperfusion 
injury [17]. Further, lutein in combination with zeaxanthine protects 
the eye cortex in age-related macular degeneration [18]. In 
addition, lutein acts as strong antioxidant due to the presence of 
hydroxyl group attached at either end of the molecule, capable of 
strong reaction with singlet oxygen than other caroteniods [19]. In a 
recent study, the antioxidant role of lutein was elucidated in 
lipopolysaccharide-induced uveitis in mice [19]. As imbalance in 
redox equilibrium and inflammation are contributing factors in 
pathogenesis of pulmonary fibrosis, we hypothesized that 
administration of lutein may alleviate the effect of pulmonary 
fibrosis. Hence, the present study is designed to investigate the 
effect of lutein on bleomycin-induced pulmonary fibrosis in mice. 
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Bleomycin sulfate and lutein were purchased from Sigma, St. 
Louis, USA. All other chemicals used in the present study were 
purchased from Hi-Media (Mumbai, India).   
Experimental Animals and Dosing  
A healthy female, pathogenic free, C57BL/6J mice weighing 20-
23g were purchased from National Institute of Nutrition 
(Hyderabad, India). All the animals were housed in polypropylene 
cages in pathogen-free experimental rooms, and were maintained 
at 22μ3oC and relative humidity of 55μ6%. Food and water were 
provided ad libitum. All experiments were performed in accordance 
with the Institutional Animal Ethics Committee. After randomization, 
the animals were divided into four groups (n=15 in each group) and 
anesthetized with intra-peritoneal injections of ketamine and 
xylazine (100 and 10 mg/kg body weight). Using aseptic 
techniques, a single incision was made at the neck, and the muscle 
covering the trachea was snipped to expose the tracheal rings. A 
single intratracheal instillation of 0.05 U bleomycin sulfate in 50 øl 
of sterile 0.9% NaCl saline was performed using a 27-gauge 
needle for groups II, III and IV. Group I animals administered orally 
with 0.5% carboxy methyl cellulose (CMC) three days prior to 
saline instillation. Group II animals administered CMC, while group 
III and IV animals orally administered with lutein at 100 and 200 
mg/kg in CMC respectively three days before the instillation of 
bleomycin. Either CMC or leutin administration continued daily for 
21 days. Appropriate numbers of mice were sacrificed on days 7 
and 21 after bleomycin administration. Bronchoalveolar lavage fluid 
(BALF) was collected for cell and protein analysis. Right lung was 
excised and stored at -80oC for biochemical assays and left lung 
was collected and stored in 10% neutral buffered formalin for 
histological analysis. 
BALF Cell Analysis 
Mice were euthanized on day 7 and the trachea was cannulated 
with intravenous polyethylene catheter equipped with 24-gauge 
needle attached to 1 mL syringe. The lungs were lavaged for four 
times with 0.8 mL of phosphate buffered saline pH 7.4 (PBS) each 
and withdrawn from the lungs via an intratracheal cannula. The 
lavage fluids were pooled and centrifuged at 1000 rpm for 10 min 
at 4oC. Total protein levels in supernatants were determined by 
BradfordÊs reagent. Total cells present in pellet were enumerated 
using trypan blue stain. Differential counting was performed using 
5% Giemsa stain by counting at least 400 cells from randomly 
chosen areas for each sample and the results were expressed as 
total number of cells/mL [20]. 
Analysis of Inflammatory Cell Infiltration and Severity of 
Fibrosis in Lung Tissues Using Histological Assessment 
The animals were euthanized by CO2 asphyxiation on 7th and 21st 
day after bleomycin instillation and lung tissues were collected. 
Tissues were fixed for one week in 10% (w/v) PBS-buffered 
formaldehyde solution at room temperature, dehydrated using 
graded alcohol and embedded in paraffin wax. After tissues were 
embedded in paraffin the tissue sections were prepared and 
stained with hematoxylin and eosin for morphometric analysis. In 
addition, trichrome and picrosirus red staining was performed for 
assessing the severity of fibrosis. The lung tissue sections were 
captured using light microscope (Olympus, C-7070, Japan). The 
severity of fibrosis was semi-quantitatively assessed as described 
earlier [21]. The grade of pulmonary fibrosis was scored on a scale 
of 0 to 8 by examining the randomly chosen sections at 40X-
magnification. The grading of pulmonary fibrosis was based on the 
following criteria: 0-normal lung; 1-minimal fibrous thickening of 
alveolar or bronchial walls; 3-moderate thickening of walls without 
obvious damage to lung architecture; 5-increased fibrosis with 
definite damage to lung structure and formation of fibrous bands or 
small fibrous masses; 7-severe distortion of structure and large 
fibrous areas and 8-total fibrous obliteration of the fields.   
Myeloperoxidase Assay (MPO) 
Tissue homogenates (10%) were prepared in 50 mM phosphate 
buffer (pH 6) containing 0.5% of hexadecyl trimethyl ammonium 
bromide and centrifuged at 20,000xg for 20 min at 4oC. The 
change in optical density (OD) in the reaction mixture (3 mL) 
containing 0.1 mL of the supernatant, 0.167 mg/mL O-dianisidine 
hydrochloride and 0.0005% of hydrogen peroxide was measured 
for 5 min at 465 nm in UV-Vis spectro photometer (Shimadzu, 
Japan). One unit of MPO activity is defined as enzyme that 
degrades 1ømole of peroxide/min at 25oC. Results were expressed 
as milli units/g tissue [22].  
Collagen Assay 
The collagen levels in lung tissues were determined by SIRCOL 
collagen assay (Biocolor Ltd., UK) according to the manufacturerÊs 
instructions. Briefly, lungs were diced and washed in cold PBS. 
The samples were subjected to acid-pepsin extraction at 4oC. Acid 
extracts were incubated with sirus red dye and absorbance was 
determined at 540 nm in UV-Visible spectrophotometer (Shimadzu, 
Japan).    
Superoxide Dismutase Assay (SOD) 
SOD activity was estimated using 10% homogenates by 
determining the enzyme ability to inhibit superoxide anion 
dependent pyrogallol autoxidation [16]. The increase in OD was 
measured in reaction mixture (3 mL) containing cytosolic extracts 
(400 øg of protein), 50 mM Tris (pH 8.0) 10 mM diethylamine 
triamine pentaacetic acid and 10 mM pyrogallol for 3 min at 420 nm 
with UV Visible spectrometer (Shimadzu, Japan). One unit of OD 
represents the amount of SOD inhibits 50% pyrogallol auto 
oxidation per min. Results were expressed as units/g tissue [23]. 
Measurement of Glutathione Levels 
Lung tissues were homogenized (10%) in buffer (0.2 M Tris-0.02 M 
EDTA, pH 8.2) and centrifuged at 15,000ïg for 30 min at 4oC. Cell-
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free extract (0.3 ml containing 1.2 mg protein) was treated with 60 
øL of 25% phosphoric acid and centrifuged at 10,000ïg for 30 min 
at 4oC to collect clear supernatant. Different aliquots of the protein-
free filtrate were made up to 0.1 mL with cold distilled water, 
followed by addition of 1.8 mL of 0.1 M sodium phosphate buffer 
(pH 8.0) containing 5 mM EDTA for glutathione or 1.8 mL of 0.1 N 
NaOH for oxidized glutathione (GSSG). To this, 0.1 mL of 1 mg/mL 
o-phthalaldehyde (OPT) was added, mixed and incubated at room 
temperature for 15 min and fluorescence intensity was measured 
at excitation and emission wave lengths of 350 and 420 nm, 
respectively using Fluoromax-3 spectrofluorimeter (Horiba Jobin 
Yvon Inc., USA). Standards ranging from 0 to 2 øg for GSSG and 
0-10 øg for GSH were evaluated simultaneously. GSH and GSSG 
react with OPT to yield a fluorescent complex and the Reduced 
glutathione (GSH) was obtained by subtracting GSSG from total 
glutathione, and molecular ratio of GSH/GSSG was calculated. 
Results and Discussion 
Effect of Lutein on Body Weights and Survival rate in 
Bleomycin-Induced Mice 
The severe lung injury caused by the bleomycin instillation was 
associated with high mortality and reduction of body weight. 0.05 U 
bleomycin instillation reduced the survival rate (48%; 7 survived out 
of 15 animals) of mice (Figure. 1A) during 10 to 21 days. In 
contrast, lutein administration at 100 and 200 mg/kg increased the 
survival rate of bleomycin-induced pulmonary fibrotic mice (group 
II) to 73% and 80%, respectively. Similarly, bleomycin instillation 
caused significant (n=15 for control, n=7 for bleomycin, p ª 0.05) 
reduction (25%) in mean body weight during 21 days of 
observation when compared to controls (group I) (Figure. S1B). 
However, the loss of body weight was insignificant in mice 
administered with lutein compared to bleomycin alone instilled 













Effect of Lutein Administration on BALF Inflammatory 
Cells in Bleomycin-Induced Mice  
To evaluate the effect of lutein in bleomycin-induced inflammation, 
the number of inflammatory cells in BALF at day 7 after bleomycin 
instillation were measured. The total number of  inflammatory cells 
in BALF were significantly (p ª 0.05) increased by 5 fold in  group II 
when compared to respective controls (Figure. S2A). However, 
lutein adminstration at 100 and 200 mg/kg significantly (p ª 0.05) 
decreased the inflammatory cells to 46.7% and 34.8% respectively 
when compared to group II animals. In addition, the differential 
count of cells present in BALF has shown a significant increase in 
lymphocytes (8.4 fold), macrophages (2.8 fold), and neutrophils 
(13.5 fold) (p ª 0.005) in group II compared to respective controls  
(Figure. 2B, 2C, and 2D). While the treatment with lutein at 100 
and 200 mg/kg significantly (p ª 0.05) decreased the lymphocytes, 
macrophages and neutrophils by 34 and 49%, 36 and 46% and 38 
and 47% respectively. In addition, total protien levels in BALF 
significantly (p ª 0.05) increased by 7.8 fold in group II comparing to 
respective controls (Figure. 2E). Such an elevated protein levels 
was significantly decreased (p ª 0.05) by 43 and 62% at 100 and 
200 mg/kg lutein administration, respectively. 
 
 




PAGE | 383 |
 
Effect of Lutein Administration on Collagen Deposition 
in Lung Tissues of Bleomycin-Induced Mice  
Accumulation of collagen is a characteristic feature of bleomycin-
induced pulmonary fibrosis. MassonÊs trichrome staining of lung 
tissues on day 21 showed an excessive deposition of collagen in 
group II with respective controls (blue color, Figure. 3A). On the 
contrary, collagen accumulation was attenuated in lutein-
administered mice at 100 or 200 mg/kg. The fibrosis score in 
blemoycin-induced mice increased up to 5.8 and was reduced to 
4.0 and 3.2 in lutein administered mice at 100 and 200 mg/kg, 
respectively (Figure. 3D). Picrosirus red staining showed similar 
pattern of collagen deposition in group II (Figure. 3B). This collagen 
deposition was reduced in lutein administered mice at 100 and 200 
mg/kg. Further, we analyzed the collagen content in lung extracts 
(Figure. 3C), which was siginificantly (p ª 0.05) increased by 2 fold 
in group II compared to controls. However, collagen content in 
mice administered with lutein at 100 and 200 mg/kg showed 
siginificant (p ª 0.05) decrease by 22.9 and 30.2% respectively 
when compared to group II.  
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Effect of Lutein Admistration on Lung Infiltartion in 
Bleomycin-Induced Mice  
Hematoxylene and Eosin staining of lung tissues revealed that 
bleomycin-induced mice showed evidences of tissue damage and 
extensive infiltration of inflammatory cells on day 7 (Figure. 4A). On 
the contrary, this massive infiltration of inflammatory cells was 
reduced in bleomycin-induced mice administered with lutein at 100 
and 200 mg/kg. A well alveolized normal lung structure was seen in 
mice instilled with saline. While severe epithelial degeneration, 
excessive deposition of extracellular matrix proteins and distorted 
alveolar architecture were observed in lungs after 21 days of 
bleomycin instillation (Figure. 4B), lungs of lutein-treated mice 
showed reduced epithelial degeneration, extracellular matrix 
deposition and restored alveolar architecture. 
In addtion, the MPO activity was measured in the lungs of 
bleomycin-induced pulmonary fibrotic mice because it is the marker 
of polymorphonuclear neutrophils infiltration (Figure. 4C). 
Bleomycin caused 92.8% increase in MPO activity significantly (p ª 
0.05) when compared to controls. However, lutein administration 
decreased the MPO activity by 24 and 30%  at 100 and  200 
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Effect of Lutein on Oxidative Stress Induced by  
Bleomycin 
Oxidative stress indicators such as SOD, GSH, and GSSG in 
bleomycin-induced lung fibrotic mice were measured. It was 
observed that GSH levels were  significantly (p ª 0.05) decreased 
by 40.8% and GSSG levels were significantly (p ª 0.05) increased 
by 77% in the lungs of group II animals when compared to group I 
(Figure. S5B and 5C). But the GSH levels were significantly (p ª 
0.05) attenuated by 40 and 47% at 100 and 200 mg/kg lutein 
administration, respectively when comapared to group II. However, 
GSSG levels significantly (p ª 0.05) decreased by 30.1 and 36.8% 
at 100 and 200 mg/kg lutein, respectively in group II.  GSH/GSSG 
levels were decreased by 66.8% in group II compared to controls. 
However, the GSH/GSSG ratio was restored up to 1.9 and 2.2 
folds in 100 and 200 mg/kg lutein-administered mice compared to 
group II (Figure. 5C). Further, SOD activity was significantly (p ª 
0.05) decreased by 35% in group II compared to controls (Fig. 5D). 
However, the SOD activity was restored by 37% and 43% at 100 
and 200 mg/kg of lutein in bleomycin-induced lung fibrotic mice 
when compared to group II. 
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Idiopathic pulmonary fibrosis is a progressive incurable disorder 
with a poor prognosis and the molecular mechanisms lying to 
cause are poorly understood. Previous reports suggested that 
inflammatory response and excessive deposition of extracellular 
matrix proteins within the pulmonary interstitium in bleomycin-
treated animals are similar to pulmonary fibrosis patients [24]. 
Hence, in the present study bleomycin was used to induce the 
pulmonary fibrosis in mice. The pulmonary fibrosis was 
characterized by significant decrease in body weights, survival 
rates, increase in inflammatory cells, including lymphocytes, 
macrophages and neutrophils, total protein in BALF, infiltration of 
polymorpho-nuclear cells in lung tissues, increase in 
myeloperoxidase activity, collagen levels, fibrosis score and 
deprival of antioxidants such as glutathione and SOD activity.  
Previous reports suggested that anti-inflammatory, anti-fibrotic and 
immunosuppressive therapies might be helpful in the treatment of 
pulmonary fibrosis, but are not effective in improving survival rate 
or quality of life [25]. However, such an altered inflammatory, 
fibrotic and oxidative stress indicators could be minimized in 
pulmonary fibrosis through natural compounds or food 
supplements, which may prevent the cause of pulmonary fibrosis at 
the initial stage of the disease. Recent studies have employed 
natural compounds extracted from various plant resources such as 
neferine, an alkaloid from Nelumbo mucifera [26], a traditional 
Chinese herbal extract of Panax notoginseng [27] and Boswellia 
serrata [28] in attenuation of bleomycin-induced pulmonary fibrosis 
in rodents. Other agents like pirfenidone, PG490-88, LLDT-8, 
taurine, niacin and corticosteroids have also shown similar effects 
in the treatment of pulmonary fibrosis because they exerted anti-
inflammatory, anti-fibrotic and antioxidant effects [26]. In the 
present study, lutein, a naturally available hydroxyl caroteniod has 
been used for determining the efficacy in preventing pulmonary 
fibrosis in bleomycin-induced mice. It was widely used as a 
protective agent in various inflammatory dysfunctions [14], 
atherosclerosis [1], endotoxin-induced uveitis [16], etc. Lutein 
administration at 100 or 200 mg/kg three days prior to intra-
tracheal instillation of bleomycin has protected the mice from 
inflammatory symptoms by reducing the number of inflammatory 
cells, including lymphocytes, macrophages and neutrophils as well 
as total protein in BALF.  Further, MPO activity in lungs was 
decreased in bleomycin-induced mice administered with lutein in 
dose-dependent manner. In addition, the present investigation 
demonstrated lutein treatment attenuated the bleomycin induced 
increase of inflammatory cells infiltration on 7th day, fibrosis score 
and collagen accumulation on 21st day. Such an anti-fibrotic effect 
was demonstrated by significant decrease of collagen levels in 
lutein-administered mice. In addition, antioxidant property of lutein 
was evidenced by dose-dependent restoration of GSH/GSSG, a 
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measure of intracellular thiol status and oxidative stress which was 
decreased followed by bleomycin instillation. It is well known that 
oxidative stress was substantiated in fibrosis lungs [8] induced by 
bleomycin administration showing symptoms of intracellular 
oxidative injury, reduction of antioxidant enzyme activities, DNA 
damage and the destruction of alveolar epithelial cells [29]. In the 
present study, depletion of GSH levels and SOD activity in 
bleomycin-induced mice indicated oxidative damage. Such 
imbalances of intracellular antioxidants in bleomycin-induced mice 
were ameliorated by leutin treatment. Similarly, previous reports 
revealed the strong antioxidant nature of lutein in 
lipopolysaccharide-induced uveitis in mice [19]. In addition, certain 
antioxidants including N-acetylcysteine, erdosteine [29] and SOD 
[6] can decrease collagen deposition and protect lungs from 
oxidative damage in variety animal models of pulmonary fibrosis 
and in human IPF.  
The results in present study suggested the anti-inflammatory, anti-
fibrotic and antioxidant role of lutein in prevention of bleomycin-
induced pulmonary fibrosis. Hence, the dietary intake of lutein may, 
perhaps, be helpful in prevention of pulmonary fibrosis. 
Statistical analysis 
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